PURPOSE: To test induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) or surgery/radiotherapy (RT) for advanced oropharyngeal cancer and to assess the effect of human papilloma virus (HPV) on response and outcome. PATIENTS AND METHODS: Sixty-six patients (51 male; 15 female) with stage III to IV squamous cell carcinoma of the oropharynx (SCCOP) were treated with one cycle of cisplatin (100 mg/m(2)) or carboplatin (AUC 6) and with fluorouracil (1,000 mg/m(2)/d for 5 days) to select candidates for CRT. Those achieving a greater than 50% response at the primary tumor received CRT (70 Gy; 35 fractions with concurrent cisplatin 100 mg/m(2) or carboplatin (AUC 6) every 21 days for three cycles). Adjuvant paclitaxel was given to patients who were complete histologic responders. Patients with a response of 50% or less underwent definitive surgery and postoperative radiation. Pretreatment biopsies from 42 patients were tested for high-risk HPV. RESULTS: Fifty-four of 66 patients (81%) had a greater than 50% response after IC. Of these, 53 (98%) received CRT, and 49 (92%) obtained complete histologic response with a 73.4% (47 of 64) rate of organ preservation. The 4-year overall survival (OS) was 70.4%, and the disease-specific survival (DSS) was 75.8% (median follow-up, 64.1 months). HPV16, found in 27 of 42 (64.3%) biopsies, was associated with younger age (median, 55 v 63 years; P = .016), sex (22 of 30 males [73.3%] and five of 12 females [41.7%]; P = .08), and nonsmoking status (P = .037). HPV titer was significantly associated with IC response (P = .001), CRT response (P = .005), OS (P = .007), and DSS (P = .008). CONCLUSION: Although the numbers in this study are small, IC followed by CRT is an effective treatment for SCCOP, especially in patients with HPV-positive tumors; however, for patients who do not respond to treatment, alternative treatments must be developed.
PURPOSE: To test induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) or surgery/radiotherapy (RT) for advanced oropharyngeal cancer and to assess the effect of human papilloma virus (HPV) on response and outcome. PATIENTS AND METHODS: Sixty-six patients (51 male; 15 female) with stage III to IV squamous cell carcinoma of the oropharynx (SCCOP) were treated with one cycle of cisplatin (100 mg/m(2)) or carboplatin (AUC 6) and with fluorouracil (1,000 mg/m(2)/d for 5 days) to select candidates for CRT. Those achieving a greater than 50% response at the primary tumor received CRT (70 Gy; 35 fractions with concurrent cisplatin 100 mg/m(2) or carboplatin (AUC 6) every 21 days for three cycles). Adjuvant paclitaxel was given to patients who were complete histologic responders. Patients with a response of 50% or less underwent definitive surgery and postoperative radiation. Pretreatment biopsies from 42 patients were tested for high-risk HPV. RESULTS: Fifty-four of 66 patients (81%) had a greater than 50% response after IC. Of these, 53 (98%) received CRT, and 49 (92%) obtained complete histologic response with a 73.4% (47 of 64) rate of organ preservation. The 4-year overall survival (OS) was 70.4%, and the disease-specific survival (DSS) was 75.8% (median follow-up, 64.1 months). HPV16, found in 27 of 42 (64.3%) biopsies, was associated with younger age (median, 55 v 63 years; P = .016), sex (22 of 30 males [73.3%] and five of 12 females [41.7%]; P = .08), and nonsmoking status (P = .037). HPV titer was significantly associated with IC response (P = .001), CRT response (P = .005), OS (P = .007), and DSS (P = .008). CONCLUSION: Although the numbers in this study are small, IC followed by CRT is an effective treatment for SCCOP, especially in patients with HPV-positive tumors; however, for patients who do not respond to treatment, alternative treatments must be developed.
Authors: Hanna Mellin; Liselotte Dahlgren; Eva Munck-Wikland; Johan Lindholm; Hodjattallah Rabbani; Mina Kalantari; Tina Dalianis Journal: Int J Cancer Date: 2002-11-10 Impact factor: 7.396
Authors: Elin Ringström; Edward Peters; Masayuki Hasegawa; Marshall Posner; Mei Liu; Karl T Kelsey Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: Michael P Mac Manus; Rodney J Hicks; Jane P Matthews; Allan McKenzie; Danny Rischin; Eeva K Salminen; David L Ball Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: David J Adelstein; Jerrold P Saxton; Pierre Lavertu; Lisa A Rybicki; Ramon M Esclamado; Benjamin G Wood; Marshall Strome; Marjorie A Carroll Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Wei Li; Carol H Thompson; Christopher J O'Brien; Edward B McNeil; Richard A Scolyer; Yvonne E Cossart; Michael J Veness; D Murray Walker; Gary J Morgan; Barbara R Rose Journal: Int J Cancer Date: 2003-09-10 Impact factor: 7.396
Authors: Wei Li; Carol H Thompson; Yvonne E Cossart; Christopher J O'Brien; Edward B McNeil; Richard A Scolyer; Barbara R Rose Journal: Head Neck Date: 2004-01 Impact factor: 3.147
Authors: Elizabeth A Sisk; Scott G Soltys; Shaobo Zhu; Susan G Fisher; Thomas E Carey; Carol R Bradford Journal: Head Neck Date: 2002-09 Impact factor: 3.147
Authors: Dirk Rades; Nina D Seibold; Maximilian P Gebhard; Frank Noack; Steven E Schild; Christoph Thorns Journal: Strahlenther Onkol Date: 2011-09-19 Impact factor: 3.621
Authors: Evgenia Gubanova; Brandee Brown; Sergei V Ivanov; Thomas Helleday; Gordon B Mills; Wendell G Yarbrough; Natalia Issaeva Journal: Clin Cancer Res Date: 2012-01-13 Impact factor: 12.531
Authors: Yin Wu; Marshall R Posner; Lisa M Schumaker; Nikolaos Nikitakis; Olga Goloubeva; Ming Tan; Changwan Lu; Sana Iqbal; Jochen Lorch; Nicholas J Sarlis; Robert I Haddad; Kevin J Cullen Journal: Cancer Date: 2011-08-25 Impact factor: 6.860
Authors: Jill Gilbert; Michelle A Rudek; Michaela J Higgins; Ming Zhao; Sara Bienvenu; Nancy Tsottles; Muhammad A Chaudhry; Richard Wahl; Arlene Forastiere; Maura Gillison Journal: Clin Cancer Res Date: 2012-01-23 Impact factor: 12.531
Authors: Kara S Davis; J Kenneth Byrd; Vikas Mehta; Simon I Chiosea; Seungwon Kim; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri Journal: Otolaryngol Head Neck Surg Date: 2014-05-08 Impact factor: 3.497
Authors: Silvana Papagerakis; Giuseppe Pannone; Li Zheng; Imad About; Nawar Taqi; Nghia P T Nguyen; Margarite Matossian; Blake McAlpin; Angela Santoro; Jonathan McHugh; Mark E Prince; Petros Papagerakis Journal: Exp Cell Res Date: 2014-05-05 Impact factor: 3.905